Journal: Biologics : Targets & Therapy

Article Title: Biosimilars in Pediatric IBD: Updated Considerations for Disease Management

doi: 10.2147/BTT.S367032

Figure Lengend Snippet: Mechanisms of Actions and Indications of EMA Approved Biologics for IBD

Article Snippet: The clinical testing of biosimilar IFX in rheumatologic diseases revealed evidence of comparability in terms of pharmacokinetics, safety, and efficacy between the reference and biosimilar IFX., CT-P13 biosimilars are marketed under a variety of brand names, including Remsima (Celltrion, Incheon, South Korea) and Inflectra (Hospira, Lake Forest, IL, USA).

Techniques:

Journal: Biologics : Targets & Therapy

Article Title: Biosimilars in Pediatric IBD: Updated Considerations for Disease Management

doi: 10.2147/BTT.S367032

Figure Lengend Snippet: Clinical Settings for Biosimilar Use in Pediatric IBD

Article Snippet: The clinical testing of biosimilar IFX in rheumatologic diseases revealed evidence of comparability in terms of pharmacokinetics, safety, and efficacy between the reference and biosimilar IFX., CT-P13 biosimilars are marketed under a variety of brand names, including Remsima (Celltrion, Incheon, South Korea) and Inflectra (Hospira, Lake Forest, IL, USA).

Techniques: Bioprocessing

Journal: Biologics : Targets & Therapy

Article Title: Biosimilars in Pediatric IBD: Updated Considerations for Disease Management

doi: 10.2147/BTT.S367032

Figure Lengend Snippet: Currently Approved Biosimilars for IBD in Europe and US

Article Snippet: The clinical testing of biosimilar IFX in rheumatologic diseases revealed evidence of comparability in terms of pharmacokinetics, safety, and efficacy between the reference and biosimilar IFX., CT-P13 biosimilars are marketed under a variety of brand names, including Remsima (Celltrion, Incheon, South Korea) and Inflectra (Hospira, Lake Forest, IL, USA).

Techniques: Bioprocessing

Journal: Biologics : Targets & Therapy

Article Title: Biosimilars in Pediatric IBD: Updated Considerations for Disease Management

doi: 10.2147/BTT.S367032

Figure Lengend Snippet: Studies Investigating the Use of CT-P13 in Pediatric IBD

Article Snippet: The clinical testing of biosimilar IFX in rheumatologic diseases revealed evidence of comparability in terms of pharmacokinetics, safety, and efficacy between the reference and biosimilar IFX., CT-P13 biosimilars are marketed under a variety of brand names, including Remsima (Celltrion, Incheon, South Korea) and Inflectra (Hospira, Lake Forest, IL, USA).

Techniques: Comparison, Biomarker Discovery

Journal: Pharmacoeconomics

Article Title: Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

doi: 10.1007/s40273-019-00841-1

Figure Lengend Snippet: Deterministic sensitivity analysis VDZ vs. IFX. ICER incremental cost-effectiveness ratio, IFX infliximab, RR relative risk, VDZ vedolizumab. *In this scenario, IFX was dominant (i.e., IFX was more effective and less costly compared with VDZ); ICER not shown. † In these scenarios, VDZ was dominant (i.e., VDZ was less costly and more effective compared to IFX); ICER not shown. ‡ In these scenarios, VDZ was less costly and less effective compared to IFX; ICER not shown

Article Snippet: IFX biosimilar was not included as a comparator as it was not considered among the treatments that are expected to be replaced when VDZ was introduced, because of the very low penetration of IFX biosimila in Japan at the time this analysis started; analyses of the Japanese claims database constructed by JMDC Inc. showed that the percentage of vials of IFX biosimilar prescribed to Japanese patients with UC among the total prescribed vials of IFX branded and biosimilar were 0.8%, 1.3%, 4.6%, and 7.1% in 2015, 2016, 2017, and 2018, respectively [ ].

Techniques:

Journal: Pharmacoeconomics

Article Title: Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

doi: 10.1007/s40273-019-00841-1

Figure Lengend Snippet: Multi-way cost-effectiveness acceptability curves. ADA adalimumab, GOL golimumab, IFX infliximab, QALY quality-adjusted life-year, VDZ vedolizumab; WTP willingness-to-pay

Article Snippet: IFX biosimilar was not included as a comparator as it was not considered among the treatments that are expected to be replaced when VDZ was introduced, because of the very low penetration of IFX biosimila in Japan at the time this analysis started; analyses of the Japanese claims database constructed by JMDC Inc. showed that the percentage of vials of IFX biosimilar prescribed to Japanese patients with UC among the total prescribed vials of IFX branded and biosimilar were 0.8%, 1.3%, 4.6%, and 7.1% in 2015, 2016, 2017, and 2018, respectively [ ].

Techniques:

Journal: Pharmacoeconomics

Article Title: Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

doi: 10.1007/s40273-019-00841-1

Figure Lengend Snippet:

Article Snippet: IFX biosimilar was not included as a comparator as it was not considered among the treatments that are expected to be replaced when VDZ was introduced, because of the very low penetration of IFX biosimila in Japan at the time this analysis started; analyses of the Japanese claims database constructed by JMDC Inc. showed that the percentage of vials of IFX biosimilar prescribed to Japanese patients with UC among the total prescribed vials of IFX branded and biosimilar were 0.8%, 1.3%, 4.6%, and 7.1% in 2015, 2016, 2017, and 2018, respectively [ ].

Techniques: Clinical Proteomics